Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma

A. William Blackstock; Al B. Benson; Masatoshi Kudo; Hugo Jimenez; Preeya F. Achari; Callum McGrath; Volker Kirchner; Lynne I. Wagner; Nathaniel S. O’Connell; Kathy Walker; Valerie K. Pasche; Ralph B. D’Agostino; Alexandre Barbault; Boris Pasche

doi:10.1051/fopen/2021003

Abstract

1 min read

Treatment of advanced HCC with the TheraBionic P1 device is well tolerated, even in patients with severely impaired liver function, and results in improved overall survival compared to historical controls without any significant adverse events, even after many years of continuous treatment. This treatment modality appears to be well suited for patients who have failed or are intolerant to currently approved therapies.

Related publications

Article2025

Development and regulatory approval of a new systemic targeted therapy for advanced hepatocellular carcinoma.

Boris Pasche, Al B. Benson, Masatoshi Kudo, Anthony F. Shields, Hugo Jimenez, Alexandre Barbault

Article2012

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

Jordi Bruix, Jean‐Luc Raoul, Morris Sherman, Vincenzo Mazzaferro, Luigi Bolondi, Antonio Craxı̀, Peter R. Galle, Armando Santoro, Michel Beaugrand, Angelo Sangiovanni, Camillo Porta, Guido Gerken, Jorge A. Marrero, Andrea Nadel, Michael Shan, M. Moscovici, D. Voliotis, Josep M. Llovet

Journal of Hepatology

Article2008

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: A subanalysis from the SHARP trial

Morris Sherman, Vincenzo Mazzaferro, D. Amadori, Julia Seitz, M. Moscovici, Ming Shan, Andrea Nadel, D. Voliotis, Josep M. Llovet, Jordi Bruix

Journal of Clinical Oncology

Article2008

Efficacy and safety of sorafenib in patients with alcohol-related hepatocellular carcinoma: A sub-analysis from the SHARP trial

Antonio Craxı̀, Camillo Porta, Angelo Sangiovanni, J.F. Seitz, M. Moscovici, Ming Shan, Andrea Nadel, D. Voliotis, Jordi Bruix, Josep M. Llovet

Journal of Clinical Oncology

Dataset

Supplementary Material for: Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study

Masatoshi Kudo, Yoon‐Koo Kang, J.-W. Park, Shukui Qin, Yoshitaka Inaba, Éric Assenat, Yoshiko Umeyama, M.J. Lechuga, Olga Valota, Yoshiro Fujii, Jean-François Martini, James A. Williams, Shuntaro Obi